10x Genomics (NASDAQ:TXG) Reaches New 1-Year High Following Strong Earnings

10x Genomics (NASDAQ:TXG) shares hit a new 52-week high on Friday following a stronger than expected earnings report. The company traded as high as $50.47 and last traded at $50.0750, with a volume of 2508566 shares changing hands. The stock had previously closed at $45.60.

The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.10. The business had revenue of $151.04 million during the quarter, compared to the consensus estimate of $146.67 million. 10x Genomics had a negative net margin of 3.55% and a negative return on equity of 2.86%. The business’s revenue for the quarter was down 12.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.28 earnings per share.

Key Headlines Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported second-quarter revenue of $151.0 million, above the $146.7 million analyst consensus, while its adjusted loss of $0.14 per share was narrower than the expected $0.24 loss. 10x Genomics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 revenue outlook to $610 million-$630 million, with the midpoint modestly above the roughly $613.8 million consensus estimate. The improved outlook was a key catalyst for the stock’s positive reaction. 10x Genomics Raises 2026 Revenue Outlook
• Positive Sentiment: Management indicated that Atera shipments remain at approximately 40 units, supporting the company’s commercial instrument rollout and potentially future recurring consumables revenue. 10x Genomics Q2 2026 Earnings Call Transcript
• Neutral Sentiment: The quarterly earnings and guidance updates were broadly ahead of expectations, but the revenue outlook represents only a modest improvement relative to analyst forecasts. 10x Genomics Q2 2026 Outlook
• Negative Sentiment: 12.7% year over year, and the company reported a loss compared with earnings of $0.28 per share in the prior-year quarter. 10x Genomics also continues to have negative margins and return on equity. 10x Genomics Reports Q2 Loss

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Stifel Nicolaus set a $50.00 price objective on 10x Genomics in a report on Friday. Piper Sandler lifted their target price on 10x Genomics from $20.00 to $42.00 and gave the stock a “neutral” rating in a report on Wednesday, July 1st. Bank of America upped their target price on 10x Genomics from $21.00 to $30.00 and gave the company a “neutral” rating in a research report on Monday, April 20th. Morgan Stanley set a $40.00 price target on shares of 10x Genomics and gave the stock an “equal weight” rating in a report on Friday. Finally, TD Cowen reissued a “hold” rating on shares of 10x Genomics in a research report on Wednesday, July 15th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, 10x Genomics presently has an average rating of “Hold” and an average price target of $34.42.

Insider Buying and Selling

In other news, CEO Serge Saxonov sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $34.44, for a total transaction of $1,033,200.00. Following the sale, the chief executive officer owned 1,108,380 shares of the company’s stock, valued at $38,172,607.20. This trade represents a 2.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Benjamin J. Hindson sold 11,595 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $24.44, for a total transaction of $283,381.80. Following the completion of the transaction, the insider owned 502,000 shares of the company’s stock, valued at approximately $12,268,880. This represents a 2.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 91,309 shares of company stock valued at $2,581,357 in the last three months. 8.84% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Geneos Wealth Management Inc. acquired a new stake in shares of 10x Genomics during the 4th quarter valued at about $38,000. Larson Financial Group LLC raised its holdings in 10x Genomics by 164.4% in the 4th quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock worth $39,000 after purchasing an additional 1,470 shares during the period. Fifth Third Bancorp acquired a new position in 10x Genomics in the 1st quarter worth about $50,000. Elevation Wealth Partners LLC boosted its position in 10x Genomics by 332.3% during the second quarter. Elevation Wealth Partners LLC now owns 1,487 shares of the company’s stock worth $57,000 after purchasing an additional 1,143 shares in the last quarter. Finally, Van ECK Associates Corp boosted its position in 10x Genomics by 85.9% during the fourth quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock worth $60,000 after purchasing an additional 1,695 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Price Performance

The company has a market capitalization of $6.37 billion, a price-to-earnings ratio of -296.56 and a beta of 2.03. The firm has a fifty day simple moving average of $38.81 and a 200 day simple moving average of $27.45.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.